Medical Centre

Influenza remains a major cause of preventable illness each winter and continues to place significant pressure on NHS general practices, urgent care services, and hospitals. This has been particularly evident this winter, with flu rates much higher than we would normally expect for this time of year.  As of mid-December 2025, UKHSA surveillance shows influenza positivity in primary-care sentinel samples running well above most pre-COVID seasons, and hospital and ICU admissions for confirmed influenza are rising sharply — especially among adults aged 65 and over and those with long-term medical conditions. In general practice, we see first-hand how flu can lead to severe complications, particularly in older adults, people with underlying conditions, and those who are immunocompromised. Vaccination remains the single most effective way to reduce the risk of severe illness, hospitalisation, and death from flu. Interim data for the 2025–26 season suggest that vaccination is already red...

Our article in the Journal of the Royal Society of Medicine argues that safe and effective AI in healthcare must incorporate mechanisms that emulate human judgement - down-weighting old, inaccurate or superseded information and prioritising what is recent, clinically relevant and reaffirmed - so that AI supports, rather than disrupts, high-quality patient care.  Clinicians constantly revise, reinterpret and filter past information so that only what is relevant, accurate and timely shapes present-day management decisions; medical records function as dynamic “working tools” rather than fixed archives. By contrast, many AI systems lack this capacity for selective forgetting and often treat all historical data as equally meaningful.  This can lead to outdated or low-confidence diagnoses being repeatedly resurfaced, persistent labels influencing clinical expectations, and irrelevant, long-resolved events cluttering summaries and decision-support outputs. Such indiscriminate recall...

The UK government’s forthcoming review of mental health and neurodevelopmental diagnoses presents an opportunity to improve the healthcare and benefits system if the potential risks are averted. Rising rates of conditions such as ADHD, autism, and anxiety disorders have raised questions about whether we are seeing a genuine increase in need or greater awareness and possible over-diagnosis. A thoughtful, evidence-based review could help bring much-needed clarity. But if mishandled, it could deepen inequalities and undermine support for those who need it most. Done well, the review could improve diagnostic quality and reduce the postcode lottery that too often defines access to assessment and treatment. Clearer clinical standards and properly funded services would allow professionals to make more accurate diagnoses, shorten long waiting lists, and better match interventions to individuals’ needs. This is an outcome everyone should welcome. But the review must not become a vehicle for re...

The announcement of a new UK-US pharmaceuticals deal is an important change in the UK’s approach to how new medicines are evaluated, priced and adopted. Faster access to innovative treatments for conditions such as cancer will be welcomed by patients and professionals. The increased investment in medicines may also help the UK attract more clinical research.  However, the impact of the proposals will depend on implementation. Raising NICE’s cost-effectiveness thresholds will increase overall NHS spending on medicines. Without a corresponding investment in areas such as workforce, diagnostics and primary care, there is a risk that higher drug spending could divert resources from other parts of the NHS. A more flexible pricing environment could also reduce the UK’s future negotiating leverage with industry. Maintaining NICE’s independence will be essential to maintain both public and professional confidence in its decision-making. The changes have could benefit patients and strength...

In an article published in the journal Frontiers in Medicine , we argue that medical education must broaden its focus: rather than treating infrastructure such as housing, transportation, energy, water supply as only a public-health or social background issue, trainees should regard infrastructural deficiencies as direct clinical determinants of patient health.  We highlight concrete examples (e.g., missed appointments due to transport failures, disrupted dialysis from electricity outages, contaminated water causing toxicity) showing how infrastructure can precipitate or worsen clinical problems. We propose educational innovations: embedding infrastructure-related history-taking, case-based learning driven by infrastructural triggers, community placements in underserved areas, and interdisciplinary learning (with urban planners, engineers, public health) to equip future clinicians with “systems-citizen” skills and advocacy capability.  The goal is to reframe clinical practice ...

I spoke to GP Registrars on the Imperial College GP Training Scheme about the evolution of medical records in primary care. This is a journey that mirrors the broader transformation of healthcare itself. The story begins in 1911 , with the introduction of the Lloyd George Envelope following the National Insurance Act. These brown paper envelopes (named after the then Chancellor and future Prime Minister, David Lloyd George), each containing a patient’s handwritten medical notes and printed correspondence, became the standard for decades. They were simple, portable, and remarkably durable but also limited by their physical nature. Searching for information meant literally leafing through these paper records, and continuity of care relied on legibility and the clinician’s diligence in recording. The late 20th century brought a revolution: the computerisation of general practice . Early adopters in the 1980s and 1990s began using systems like EMIS and Vision, digitising the record and ...

There has been recent discussion about the need to revise drug pricing frameworks within the United Kingdom's National Health Service (NHS), particularly amid the ongoing transatlantic trade frictions involving potential tariffs from the United States administration. Elevating the cost-effectiveness threshold applied by the National Institute for Health and Care Excellence (NICE) by 25 percent from its established range of £20,000 to £30,000 per quality-adjusted life year (QALY) would increase access for NHS patients to innovative treatments that were previously excluded on grounds of excessive cost relative to their clinical benefits.  However, this change would also put increased pressure on the NHS budget. It is difficult to quantify the extra spending that might result from a wider range of drugs becoming available for use in the NHS through this change but any extra spending on these treatments would have to be matched by reductions in spending on other health services. Effect...